___

• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999, CA Cancer J Clin 1999;49:8-31.
• Fiorca JV, Roberts WS. Screening for ovarian cancer. Cancer Control 1996;3(2):120-129.
• Conti PS, Lilien DL, Hawley K, et al. PET and FDG in oncology: a clinical update. Nucl Med Biol 1996;23(6):717-35.
• Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32(4):623-48.
• Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329(21):1550-9.
• Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5(1):26-35.
• Morrow CP, Curtin JP, Townsend DE. Tumors of the ovary: classification of the adnexal mass. In: Synopsis of gynecologic oncology. 4th Ed. New York: Churchill Livingstone, 1993:265.
• Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4(1):1-12.
• Niloff JM, Bast RC Jr, Schaetzl EM, et al. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985;151(7):981-6.
• Patsner B, Orr JW Jr, Mann WJ Jr, et al. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990;38(3):373-6.
• Method MW, Serafini AN, Averette HE, et al. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. Cancer 1996;77(11):2286-93.
• Ferrozi F, Bova D, De Chiara F, et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imag 1998;22(5):364-70.
• Uysal U, Kostakoğlu L, Elahi N, et al. Can bone scintigraphy detect additional metastatic sites unrevealed by CT in patients with recurrent ovarian carcinoma? Radiat Med 1997;15(1):55-58.
• Giunta S, Venturo I, Mottolese M, et al. Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology. Gynecol Oncol 1994;53(1):103-8.
• Garcia–Velloso MJ, Jurado M, Ceamanos C, et al. Diagnostic accuracy of FDG PET in the follow-up of palatinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 2007;34(9):1396-405.
• Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. Value of 18-FDG PET, CT and magnetic resonance imaging in diagnosis primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10(5):761-7.
• See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status are future prospects. Int J Gynecol Cancer 2003;13(6):701-34.
• Henkin RE, Bova D, Dillehay GL, et al. Nuclear Medicine 2nd edition, 1st volume, Pennsylvania: Mosby Elsevier; 2006: 257-85.
• Kapoor V, McCook BM, Torok FS. An Introduction to PET-CT Imaging. Radiographics 2004;24(2):523-43
• Berry JD, Cook GJR. PET in oncology. British Medical Bulletin 2006;79(80):171-86.
• Gallagher BM, Anasri A, Atkins M, et al Radiopharmaceuticals XXVII. 18F- FDG metabolism in vivo. Tissue distribution and imaging studies in animals. J Nucl Med 1977;18(10):990-6.
• Shalom RB, Valdivia AY, Blaufox MD. PET imaging in oncology. Seminars in Nuclear Medicine 2000;30(3):150-85.
• Ruhlman J, Oehr P, Biersack HJ (eds). PET in Oncology: Basic and Clinical Applications. Berlin Heidelberg: Springer, 1999:89–101.
• Dominique D, Edward C, Milton G, et al. Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT. http://jnm.snmjournals.org/cgi/reprint/47/5/885.pdf.
• Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-(18F) deoxyglucose (2-18F FDG). Gynecol Oncol 1993;51(2):197-204.
• Schröder W, Zimny M, Rudlowski C, et al. The role of 18-F-FDG PET in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9(2):117-22.
• Zimny M, Schröder W, Wolters S, et al. FDG PET in ovarian carcinoma: methodology and preliminary results. Nuklearmedizine 1997;36(7):228-33.
• Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynocol Oncol 2000;77(3):454-9.
• Zimny M, Siggelkow W, Schroder W et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83(2):310-5.
• Sella T, Rosenbaum E, Edelmann DZ, et al. Value of chest CT scans in routine ovarian carcinoma follow- up. AJR Am J Roentgenol 2001; 177(4):857-9.
• Sebastian S, Lee SI, Horowitz NS et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008; 33(1):112-8.
• Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29 (6):797-803.
• Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233(2):433-40.
• Torizuka T, Nobezavwa S, Kanno T, et al. Ovarian cancer recurrence: role of whole–body positron emission tomography using 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 2002;29(6): 797–803.
• Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989;160(3):667-71.
• Martinez-Roman S, Ramirez PT, Oh J, et al. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 2005;96(3):888–91.
• Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR 2000;174(4):1005-8.
• Chung HH, Kang WJ, Kim JW, et al. Role of FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clincal or histological findings. Eur J Nucl Med Mol Imaging 2007; 34(4):480-6.
• Alla T, Henry W Yeung , Aida Sanchez S, et al. Peritoneal Carcinomatosis: Role of FDG-PET. J Nucl Med 2003; 44(9):1407-12.
• Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-(fluorine-18)- fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51(2):175-81.
• Kubik-Huch RA, Dorffler W, Von Schulthess GK, et al. Value of 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10(5):761-7.
• Rose PG, Faulhaber P, Miraldi F, et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82(1):17-21.
• Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001;176(6):1449-54.
• Schroder W, Zimny M, Rudlowski C, et al. The role of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose ( 18 F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9(2):117-122.